Source: Virtual Congress 2020 – Pharmacological management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. Antonov (Chelyabinsk (Chelyabinsk Oblast), Russian Federation), G. Ignatova (Chelyabinsk (Chelyabinsk Oblast), Russian Federation). Influence of vaccine prevention of pneumoccocus conjugated vaccine on mortality in patients with COPD. 2425

Member's Comments

No comment yet.

Related content which might interest you: Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Annual Congress 2007 - Different aspects of COPD exacerbations Year: 2007 Effects of pneumococcal vaccine in patients with chronic respiratory disease Source: Eur Respir Rev 2008; 17: 43-45 Year: 2008 Protective effect of pneumococcal vaccine against death by pneumonia in elderly subjects Source: Eur Respir J 2005; 26: 1086-1091 Year: 2005 Effectiveness of the pneumococcal polysaccharide vaccine in preventing pneumonia in the elderly Source: Eur Respir J 2010; 36: 608-614 Year: 2010 Additive preventive effect of influenza and pneumococcal vaccines in elderly persons Source: Eur Respir J 2004; 23: 363-368 Year: 2004 Efficacy of influenza and pneumococcal vaccinations among patients with COPD Source: Annual Congress 2007 - Treatment of COPD Year: 2007 Effectiveness data on prevention of COPD exacerbations with 13-valent pneumococal conjugate vaccine (PCV13) Source: International Congress 2017 – Discussion of vaccines, biomarkers and risk factors analysis   Year: 2017 No preventive effects of 23-valent pneumococcal polysaccharide vaccine in patients with chronic renal failure Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13) Source: International Congress 2016 – Microbiological issues and translational research in respiratory infections Year: 2016 Aetiology of paediatric pneumonia after the introduction of pneumococcal conjugate vaccine Source: Eur Respir J 2013; 42: 1595-1603 Year: 2013 Analysis of the Effect of pneumococcal vaccination in patients with COPD in combination with bronchiectasis Source: Virtual Congress 2021 – Bronchiectasis and pleural infection Year: 2021 Vaccination of COPD patients with a pneumococcus type 6B tetanus toxoid conjugate vaccine Source: Eur Respir J 2002; 20: 813-818 Year: 2002 Societal perspective and challenges of influenza and pneumococcal vaccination in patients at risk of respiratory complications Source: Annual Congress 2008 - Why vaccinate patients with chronic respiratory conditions? Today and tomorrow's perspectives Year: 2008 Cost-effectiveness of adult pneumococcal conjugate vaccination in the Netherlands Source: Eur Respir J 2015; 46: 1407-1416 Year: 2015 Previous pneumococcal polysaccharide vaccine impacts immune response to subsequent pneumococcal conjugate vaccine in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 673s Year: 2005 Perception and uptake of the influenza and pneumococcal vaccinations in patients with COPD Source: Annual Congress 2008 - Organisation of care and management of COPD Year: 2008 Effectiveness of a 23-valent pneumococcal polysaccharide vaccine and a 13-valent pneumococcal conjugate vaccine among the elderly with chronic respiratory diseases Source: International Congress 2018 – Pneumonia: from the community to the intensive care unit Year: 2018 Can the influenza vaccine response be predicted in COPD patients by clinical parameters? Source: International Congress 2015 – Treatment and control of respiratory disease Year: 2015 Comparison of efficacy of grippe vaccination and broncho vaxom administration in COPD patients Source: International Congress 2015 – Different data in COPD Year: 2015 Impact of influenza vaccination in patients with CAP Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009